Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
about
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular eventsEfficacy and Safety of Alogliptin in Patients With Type 2 Diabetes: Analysis of the ATTAK-J Study.Dipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes.GPR119 Agonist AS1269574 Activates TRPA1 Cation Channels to Stimulate GLP-1 Secretion.Effectiveness and Safety of Sitagliptin in Patients with Beta-thalassaemia Major and Diabetes Mellitus: A Case Series.Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale.Pharmacokinetics and clinical evaluation of the alogliptin plus pioglitazone combination for type 2 diabetes.An overview of new GLP-1 receptor agonists for type 2 diabetes.Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation.Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes.Investigational insulin secretagogues for type 2 diabetes.Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes.Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development.Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes.DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.Chronic unpredicted mild stress-induced depression alter saxagliptin pharmacokinetics and CYP450 activity in GK ratsDipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid TumorA randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus.Dapagliflozin and saxagliptin tablets for adults with type 2 diabetes.Pharmacological management of type 2 diabetes: what's new in 2017?Pancreatic Safety of Sitagliptin in the TECOS Study.Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
P2860
Q33696974-08E87EB7-572A-4C1D-82CF-1FE55E109FBCQ35736564-B9A8F296-EA00-4342-B189-34E445CFFDE0Q36429742-A6F6715A-D80F-4D8A-9D71-E67510C420B4Q36466692-2017BC91-DB13-4130-99EA-D059BAAF11F2Q36856980-81BF061B-0FE1-4884-991E-13B1AC4FE60EQ36945211-9B3C3F90-CF4D-4BDD-97B9-1F2045B4612EQ37577871-8B7F2079-7FF0-4F07-8141-059E23EBE471Q37722896-4E90C6DD-F63C-433C-AFC0-38B1D94236DBQ38455771-C478D732-8304-4895-9EF3-D87BE5AC0508Q38639922-F1569CC7-662D-48D7-8C21-F2732C324FCFQ38647717-40386928-981D-4CDC-ACBA-2C411B421117Q38734181-ADF176FC-7963-4952-A2DF-F1508D99C5C6Q38735419-195ECD5F-360F-4576-8737-047097A5E87AQ38815498-5AB6D3B0-4C6F-4D81-9CE0-2CA8CDCA58A5Q38832716-12347183-80A5-4DEE-B5C2-1D2D286AA342Q38856808-A4015101-EFEE-4488-9A8F-9F2A724195AEQ38902321-8FED8C93-1266-43A4-BCAB-63CA2A944430Q39000172-711817A4-3402-48CE-890D-09CA7612B9F9Q39063447-680270CF-D91E-4ED7-ACFE-CE810B64F7DAQ39189383-CF9D9263-6D89-445F-B6C8-EC167470F207Q41992765-4E5BAD5B-5A74-4B8D-9E0C-36DACA4735AEQ42036384-B34BD649-E0A6-42A4-B6B4-B0CF0EA511DAQ45983099-3F3C3BA0-298F-4490-B439-65285C93588EQ47326370-E49CC8BB-FE2F-4BAC-AEE1-9A2E50CD70C1Q47687852-BCEF6735-A81E-49F9-B502-63E620B15289Q47696671-BCA49F5F-FDED-4221-8323-E43FF3CFCBC1Q50219805-FA35F5F9-13C8-4ECE-B2B0-B58AF4D3435FQ55053753-125C8E0C-18B2-4460-92E7-583C85F8B2BC
P2860
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
@en
type
label
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
@en
prefLabel
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
@en
P2860
P1476
Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes.
@en
P2093
André J Scheen
P2860
P304
P356
10.1517/14740338.2015.1006625
P407
P577
2015-01-29T00:00:00Z